
What if healing bone no longer required harvesting bone? 🦴 A 2026 trial involving 183 patients found a PTH-based bone graft substitute non-inferior to autograft, with 83.6% union at 16 weeks in the high-dose group [1]. But the evidence gap remains. A 2026 review found only 15 eligible studies across 1,751 screened papers [2]. 🚀 For orthopedic innovators, the opportunity extends beyond biomaterials: fewer donor-site complications, better recovery and stronger clinical evidence. The priority? Prove long-term outcomes, safety and cost-effectiveness before scaling adoption. 🤔 Should synthetic bone grafts become the new standard, or is clinical evidence still too limited? Sources: [1] [ncbi.nlm.nih.gov/pubmed/4153…](ncbi.nlm.nih.gov/pubmed/4153…) [2] [ncbi.nlm.nih.gov/pubmed/4210…](ncbi.nlm.nih.gov/pubmed/4210…) [3] [ncbi.nlm.nih.gov/pubmed/4258…](ncbi.nlm.nih.gov/pubmed/4258…) #Orthopedics #BoneGrafts #Biomaterials #MedTech
